Medchemexpress/TAK-438(Synonyms: Vonoprazan Fumarate)/HY-15295/10mM*1mL in DMSO_蚂蚁淘，【正品极速】生物医学科研用品轻松购|ebiomall 蚂蚁淘商城

商品信息

联系客服

Medchemexpress/TAK-438(Synonyms: Vonoprazan Fumarate)/HY-15295/10mM*1mL in DMSO

郑重提醒：

无质量问题不接受退换货，下单前请仔细核对信息。

下单后请及时联系客服核对商品价格，订单生效后再付款。

Medchemexpress/TAK-438(Synonyms: Vonoprazan Fumarate)/HY-15295/10mM*1mL in DMSO

品牌 /

MedChemExpress

货号 /

HY-15295-10mM*1mLinDMSO

官网地址

美元价：

登录查看

(友情提示：该价格仅为参考，欢迎联系客服询价！)

数量：

免费咨询热线

4000-520-616

商品介绍售后保障相关文章商品咨询

联系客服

TAK-438isanovelP-CAB(potassium-competitiveacidblocker)thatreversIBLyinhibitsH+/K+,ATPasewithIC50of19nM(pH6.5),controlsgastricacidsecretion.

Description	TAK-438isanovelP-CAB(potassium-competitiveacidblocker)thatreversiblyinhibitsH+/K+,ATPasewithIC50of19nM(pH6.5),controlsgastricacidsecretion.IC50value:19nM[1]Target:H+/K+ATPaseinvitro:TAK-438isapyrrolederivativewithachemicalstructurethatiscompletelydifferentfromtheP-CABsdevelopedtodate.TAK-438inhibitsgastricH+,K+-ATPaseactivityinaconcentration-dependentmanner.Underneutralconditions(pH7.5),theinhibitoryactivityofTAK-438isalmostthesameasthatunderweaklyacidicconditions(pH6.5).TAK-438doesnotinhibitNa+,K+-ATPaseactivityevenatconcentration500timeshigherthantheirIC50valuesagainstgastricH+,K+-ATPaseactivity.TAK-438inhibitsgastricH+,K+-ATPaseinaK+-competitivemannerwithKiof3nM[2].invivo:TAK-438inhibitsbasalgastricacidsecretioninadose-dependentmanner,andtheID50valueis1.26mg/kg.IntravenousadmiNISTrationofTAK-438dose-dependentlyincreasesthepHofthegastricperfusate,andtheincreaseinpHissustainedfor5hafteradministration.Atthe1mg/kgdose,thepHplateaues90minafteradministration,andthehighestpHvaluereachedis5.9[2].Inaddition,TAK-438showsapotentandlonger-lastinginhibitoryeffectonthehistamine-stimulatedgastricacidsecretioninratsanddogs.TAK-438showssignificantantisecretoryactivitythroughhighaccumulationandslowclearancefromthegastrictissue.TAK-438isunaffectedbythegastricsecretorystate,unlikePPIs[3].
References	[1].ArikawaY,etal.Discoveryofanovelpyrrolederivative1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate(TAK-438)asapotassium-competitiveacidblocker(P-CAB).JMedChem,2012,55(9),4446-4456. [2].HoriY,etal.1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminemonofumarate(TAK-438),anovelandpotentpotassium-competitiveacidblockerforthetreatmentofacid-relateddiseases.JPharmacolExpTher,2010,335(1),231-238. [3].HoriY,etal.AstudycomparingtheantisecretoryeffectofTAK-438,anovelpotassium-competitiveacidblocker,withlansoprazoleinanimals.JPharmacolExpTher,2011,337(3),797-804.

Description

TAK-438isanovelP-CAB(potassium-competitiveacidblocker)thatreversiblyinhibitsH+/K+,ATPasewithIC50of19nM(pH6.5),controlsgastricacidsecretion.IC50value:19nM[1]Target:H+/K+ATPaseinvitro:TAK-438isapyrrolederivativewithachemicalstructurethatiscompletelydifferentfromtheP-CABsdevelopedtodate.TAK-438inhibitsgastricH+,K+-ATPaseactivityinaconcentration-dependentmanner.Underneutralconditions(pH7.5),theinhibitoryactivityofTAK-438isalmostthesameasthatunderweaklyacidicconditions(pH6.5).TAK-438doesnotinhibitNa+,K+-ATPaseactivityevenatconcentration500timeshigherthantheirIC50valuesagainstgastricH+,K+-ATPaseactivity.TAK-438inhibitsgastricH+,K+-ATPaseinaK+-competitivemannerwithKiof3nM[2].invivo:TAK-438inhibitsbasalgastricacidsecretioninadose-dependentmanner,andtheID50valueis1.26mg/kg.IntravenousadmiNISTrationofTAK-438dose-dependentlyincreasesthepHofthegastricperfusate,andtheincreaseinpHissustainedfor5hafteradministration.Atthe1mg/kgdose,thepHplateaues90minafteradministration,andthehighestpHvaluereachedis5.9[2].Inaddition,TAK-438showsapotentandlonger-lastinginhibitoryeffectonthehistamine-stimulatedgastricacidsecretioninratsanddogs.TAK-438showssignificantantisecretoryactivitythroughhighaccumulationandslowclearancefromthegastrictissue.TAK-438isunaffectedbythegastricsecretorystate,unlikePPIs[3].

References

[1].ArikawaY,etal.Discoveryofanovelpyrrolederivative1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate(TAK-438)asapotassium-competitiveacidblocker(P-CAB).JMedChem,2012,55(9),4446-4456.
[2].HoriY,etal.1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminemonofumarate(TAK-438),anovelandpotentpotassium-competitiveacidblockerforthetreatmentofacid-relateddiseases.JPharmacolExpTher,2010,335(1),231-238.
[3].HoriY,etal.AstudycomparingtheantisecretoryeffectofTAK-438,anovelpotassium-competitiveacidblocker,withlansoprazoleinanimals.JPharmacolExpTher,2011,337(3),797-804.

PreparingStockSolutions

ConcentrationVolumeMass	1mg	5mg	10mg

1mM	2.1670mL	10.8352mL	21.6704mL
5mM	0.4334mL	2.1670mL	4.3341mL
10mM	0.2167mL	1.0835mL	2.1670mL

Pleaserefertothesolubilityinformationtoselecttheappropriatesolvent.

References

[1].ArikawaY,etal.Discoveryofanovelpyrrolederivative1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminefumarate(TAK-438)asapotassium-competitiveacidblocker(P-CAB).JMedChem,2012,55(9),4446-4456.
[2].HoriY,etal.1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanaminemonofumarate(TAK-438),anovelandpotentpotassium-competitiveacidblockerforthetreatmentofacid-relateddiseases.JPharmacolExpTher,2010,335(1),231-238.
[3].HoriY,etal.AstudycomparingtheantisecretoryeffectofTAK-438,anovelpotassium-competitiveacidblocker,withlansoprazoleinanimals.JPharmacolExpTher,2011,337(3),797-804.

MolecularWeight

461.46

Formula

C₂₁H₂₀FN₃O₆S

CASNo.

1260141-27-2

Storage

Powder	-20°C	3years
	4°C	2years
Insolvent	-80°C	6months
	-20°C	1month

Shipping

RoomtemperatureincontinentalUS;mayvaryelsewhere

Solvent&Solubility

10mMinDMSO

*"<1 mg/ml"="" means="" slightly="" soluble="" or="" insoluble.="" "≥"="" means="" soluble,="" but="" saturation="">

Purity:99.97%

SelectBatch: